Expert oncologist Matthew Smith, MD, PhD, reviews efficacy and safety data from the phase 3 ARASENS study combining darolutamide with ADT and docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC
Enzalutamide Improves Undetectable PSA Rates Alone and With Leuprolide in Nonmetastatic CSPC
FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC
Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
18F-PSMA-1007 PET/CT Provides Staging Benefit Over MRI in Prostate Cancer
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
Novel CDK4 Inhibitor Shows Activity and Safety in HR+/HER2– Metastatic Breast Cancer
Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer